Autoimmune Disease Diagnostics Market: Growing Awareness Among People About Autoimmune Diseases Drives the Market Growth
Technological advancements in the medicals sector are also fueling the market’s growth. Between 2015 and 2023, the global autoimmune diseases diagnostics market is expected to exhibit a CAGR of 3.8%. The global autoimmune disease diagnostics market is likely to reach US$17.06 bn by 2023. The stiff price competition among players is expected to impact the growth of the market in a negative way.
Browse Market Research Report @ http://www.transparencymarketresearch.com/autoimmune-disease-diagnostics-market.html
North America to Continue to Lead in the Autoimmune Disease Diagnostics Market
By geography, North America is expected to lead in the autoimmune disease diagnostics market with the U.S. and Canada contributing the most to the market in the region. These countries have sophisticated healthcare infrastructure and laboratories with advanced techniques. There also exists high level of awareness regarding various medical procedures. The increased healthcare expenditure in the region will also be a contributing factor to the growth of the market in region. Asia Pacific is also expected to witness a rapid growth in the autoimmune disease diagnostics market on account of high demand from countries such as Malaysia, Australia, India, Japan, and China. Advancements in diagnostics devices will push the Asia Pacific autoimmune disease diagnostics market towards witnessing a CAGR of 4.3% between 2015 and 2023.
High Occurrence of Rheumatoid Arthritis to Drive Autoimmune Disease Diagnostics Market
Autoimmune diseases such as Graves’ disease, Hashimoto’s thyroiditis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and type1 diabetes are prevalent commonly. Of these, the most prevalent of all diseases is rheumatoid arthritis, which can occur to people falling under any age group. The rheumatoid arthritis segment is estimated to be worth US$4.6 bn by the end of 2022. The growing geriatric population and improved diagnosis of rheumatoid arthritis at improved laboratories will drive the segment towards growth in the coming year. Apart from rheumatoid arthritis, the type 1 diabetes segment is expected to show a healthy growth and exhibit a CAGR of 3.7% between 2015 and 2023.
For more information on this report, fill the form @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5351
Unavailability of Trained Professionals to Result in Operational Challenges
There is a dearth of trained professionals in the market which will hamper the growth of this market. In addition to this, a lack of automation will also pose a challenge and hamper the operations in clinical laboratories. Further, the threat of new entrants, mostly local players, will cause leading players to cut down their prices. Slashing down the prices of diagnostic devices so as to stay in the market and remain competitive is projected to have an adverse impact on the global autoimmune disease diagnostics market.
However, on the plus side, the market for autoimmune disease diagnostics is expected to find new opportunities for growth as leading players will leverage the untapped markets in emerging nations and capitalize on them. Players are also expected to concentrate on replacing traditional technologies with latest ones and automate the laboratories. This will help the market to grow. Additionally, the introduction of novel technologies will create promising growth for the market.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Autoimmune Disease Diagnostics Market: Growing Awareness Among People About Autoimmune Diseases Drives the Market Growth here
News-ID: 587919 • Views: 185
More Releases from Transparency Market Research
Hip Replacement Implants Market to reach US$ 9.0 Bn by 2026 - TMR
Hip Replacement Implants Market – Snapshot The global hip replacement implants market is estimated to be driven by rise in geriatric population and augmented demand for hip arthroplasty/replacement surgical procedures. In addition, high incidences of lower extremity conditions like various hip ailments, osteoporosis, and Osteoarthritis (OA) are further likely to bolster the growth of the global hip replacement implants market. Increased availability of affordable healthcare facilities in many developed countries together with
Life Sciences BPO Market to Perceive Substantial Growth by the End 2027
AI and ML Provide Actionable Insights for Intelligent Drug Discovery Gene therapies, intelligent drug discovery, telemedicine, and the likes are bringing about a change in the life sciences BPO market. Companies in the market for life sciences BPO are innovating through AI and machine learning (ML) for drug discovery. For instance, in June 2019, Navitas Life Sciences— a company that delivers platform-driven clinical solutions and services, announced to partner with ThoughtSphere—
Hematology Diagnostics Market to Reach Approximately US$ 5,586.4 Mn by 2026
The vendor landscape of the global market of hematology diagnostics features a handful of companies collectively accounting for a large share in the overall market, hinting at a largely consolidated vendor landscape, observes Transparency Market Research in a recent report. Companies such as Sysmex Corporation, Abbott Laboratories, Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd. command dominance owing to their expansive product portfolios and well-established distribution channels globally. Read Report Overview -
Endoscopic Ultrasound Needles Market to Expand at a CAGR of 4.4% from 2017 to 20 …
The global endoscopic ultrasound needles market was valued at around US$ 139.2 Mn in 2016 is anticipated to expand at a stable CAGR of over 4.5% during forecast period of 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled ’Endoscopic Ultrasound Needles Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025.’ Read Report Overview - https://www.transparencymarketresearch.com/endoscopic-ultrasound-needles-market.html Expansion of the global endoscopic ultrasound needles
More Releases for Autoimmune
Autoimmune Disease Therapeutics Market Boost due to increase in incidence of aut …
According to a new report published by Allied Market Research, titled,"Autoimmune Disease Therapeutics Market by Drug Class, Indication, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025," the global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is expected to reach $153,320 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025. Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/5185?utm_source=openpr&utm_medium=Niranjan Autoimmune disease therapeutics include
Autoimmune Treatment Market North America Leads the Global Autoimmune Treatment …
The global autoimmune treatment market is growing significantly due to increasing incidences of autoimmune diseases, up surging healthcare expenditure, and advancements in the technologies for the development of autoimmune diseases therapeutics. Autoimmune diseases are chronic in nature and do not have permanent treatment. This creates ample growth opportunity for the autoimmune treatment market, to grow at a considerable rate in the coming years. The advanced research and development facilities, and
Autoimmune Disease Diagnostics Market: Rise in Autoimmune Diseases, alongside Gr …
Global Autoimmune Disease Diagnostics Market: Snapshot The global autoimmune disease diagnostics market is expected to witness a modest growth in the coming years on account of the growing incidences of autoimmune diseases among people worldwide. Efficient autoimmune disease diagnostics has become absolutely essential to tackle this issue. Governments across nations are also increasing their spending towards healthcare in light of these growing incidences of autoimmune diseases. This has also resulted in
Autoimmune Disease Diagnostics Market Growth Analysis 2023
Despite its vendor landscape being highly consolidated, intense rivalry prevails among key players in The Global Autoimmune Disease Diagnostics Market. According to Transparency Market Research (TMR), the top four companies held over 50% of the global autoimmune disease diagnostics market in 2014. Among the leading enterprises, F. Hoffmann-La Roche Ltd. held the dominant share of over 17% in the market in the same year. In response to the increasing demand for
Global Autoimmune Treatment Market Research Report 2017
Global Autoimmune Treatment Industry 2017 Market Overview, Size, Share, Trends, Analysis, Technology, Applications, Growth, Market Status, Demands, Insights, Development, Research and Forecast 2017-2020. The research report on global Autoimmune Treatment market offers an in-depth analysis, presenting insights into the key growth factors, which are estimated to encourage growth of the global market. In addition, the research study throws light on the drivers, barriers, latest opportunities, current trends, and the technological developments
Autoantibody Diagnostics in Autoimmune Liver Diseases
ORGENTEC Diagnostika (www.orgentec.com) has developed four new laboratory tests for the diagnosis of autoimmune liver diseases. These tests are now on the market. They are based on ELISA technology and were specifically developed for fully automated analysis with Alegria®. The new tests systems, called Anti-Sp100, Anti-gp210, Anti-LKM-1, and Anti-SLA, reliably detect specific autoantibodies that are characteristic of various autoimmune liver diseases. The tests thus also allow for reliable differentiation between these